Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

0
19
Processa Pharmaceuticals, Inc. announced the successful completion of the safety tolerability evaluation in its Phase Ib trial of Next Generation Capecitabine.
[Processa Pharmaceuticals, Inc.]
Press Release